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MRC Faces Rockier Road Ahead
The UK’s Medical Research Council is losing a charismatic leader, who has worked hard to broaden 
the agency’s remit and who will depart at a time of financial uncertainty for British research.Leszek Borysiewicz, known as Borys, 
has firmly stamped his authority on the 
UK’s Medical Research Council (MRC) 
since arriving as its chief executive in 
October 2007. But last November, he 
shocked British biomedical researchers 
by announcing that he will depart this 
autumn to become Vice-Chancellor of 
the University of Cambridge. The Cam-
bridge job is, of course, a pinnacle of 
European higher education. Nonethe-
less, there’s an acute sense of loss at 
the MRC’s London headquarters that 
Borys will be moving on, after instigat-
ing extensive reforms that have shifted 
the orientation of the research council 
firmly in the direction of applied sci-
ence. “A lot of people will be very dis-
appointed,” says a former MRC offi-
cial, recalling a tumultuous period that 
preceded Borysiewicz’s appointment. 
“He’s done a fantastic job of calming 
the place down.”
More significantly, Borysiewicz (Fig-
ure 1), an immunologist and physician 
who made his name developing a vac-
cine to treat cervical cancer, and a for-
mer deputy rector of Imperial College 
London, has steered the MRC toward 
a much stronger emphasis on transla-
tional medicine, without disrupting its 
core strengths in basic research. He 
notes that in so doing, the MRC is return-
ing to its roots. Although dominated by 
basic biology, as Borysiewicz noted at a 
December meeting of MRC grantees in 
Edinburgh, the MRC’s very first opera-
tion, when it opened in 1913, was an 
office of health statistics.
“The main achievement has been 
developing translation without hurt-
ing basic research,” says Borysiewicz 
of his period in charge. “We’ve had to 
build up partnerships with the National 
Health Service [NHS], the universities 
and with business. We’ve also been able 
to deliver really high-class science, win-
ning two Nobel Prizes [Martin Evans for 
embryonic stem cells in 2007 and Ven-
katraman Ramakrishnan for his work on the ribosome last year] and we’ve estab-
lished the MRC firmly on the international 
health agenda.”
Borys arrived at the MRC in 2007, with 
a Polish-tinged Welsh accent, warmth of 
manner, and almost boyish enthusiasm. 
The research council had just received 
fresh and contentious marching orders 
from the Cooksey Report (http://www.
hm-treasury.gov.uk/cooksey_review_
index.htm). The report, prepared by 
venture capitalist David Cooksey for 
Gordon Brown, who was then Chancel-
lor of the Exchequer (finance minister), 
called for the restructuring of British 
medical research to improve its contri-
bution to the economy and to national 
 healthcare.
The big quandary, from the govern-
ment’s perspective, was this: Britain has 
both the MRC, with 28 Nobel Prizes to 
Figure 1. MRC Leader Is Moving on
The chief executive of the UK’s Medical Research 
Council (MRC), Leszek Borysiewicz, last Novem-
ber announced that he will be leaving the MRC to 
become Vice-Chancellor of the University of Cam-
bridge. Photo courtesy of Noel Murphy/Medical 
Research Council.Cell 140its name, and the Wellcome Trust, the 
world’s largest research charity, invest-
ing in biomedical research. It is also 
headquarters to several major phar-
maceutical companies and has, in its 
National Health Service, potential for a 
unified database of more than 40 million 
patients. But its biotechnology sector 
has struggled to get off the ground. And 
with the US National Institutes of Health 
(NIH) spending $30 billion a year on bio-
medical research, compared with $5 
billion (£3 billion) by the UK government 
and charities combined, it is not clear 
how the UK can stay fully competitive.
A full merger between the MRC and 
the NHS’s National Institute for Health 
Research (NIHR) was considered and 
rejected by the Cooksey Report (much to 
the relief of basic researchers). Instead, 
significant extra resources (£300 mil-
lion over 3 years) were allocated to the 
translation of research findings into 
healthcare, and a new Office for Stra-
tegic Coordination of Health Research 
(OSCHR) was established to coordinate 
the national effort.
The impact of these changes is already 
visible, including 78 new MRC awards 
for translational research, as well as the 
establishment of five general and seven 
specialized biomedical research centers 
for use by NIHR and MRC research-
ers at major British teaching hospitals. 
“These investments are giving us an 
infrastructure that MRC researchers can 
take advantage of,” says Borysiewicz. “I 
think they’ve made remarkable progress, 
and just as remarkably, they are actually 
working together.” The new arrange-
ments are due to be reviewed in 2011 for 
their effectiveness in meeting the Cook-
sey Report’s objectives.
“I think Borys has produced quite a 
significant cultural change at the MRC,” 
says John Bell, Regius Professor of Medi-
cine at the University of Oxford and chair 
of OSCHR. “He’s made it much more 
outward looking, more part of the wider 
health research family.” Basic research-, February 5, 2010 ©2010 Elsevier Inc. 303
ers at the MRC—concerned prior to 
Borys’ appointment that the research 
council would close some intramural labs 
and move away from basic research—
“have been reassured” by his tenure, Bell 
says. “The basic scientists have fallen in 
behind the new model. The reality is that 
some of the greatest beneficiaries of the 
new arrangements are basic scientists.” 
Mark Walport, Director of the Wellcome 
Trust, agrees that Borysiewicz has suc-
cessfully moved the MRC toward the 
translation agenda and says that fears 
that this would hurt basic research have 
proven to be “groundless.”
Michael Schneider, an American 
molecular geneticist who moved to the 
UK National Heart and Lung Institute 
at Imperial College London from Baylor 
College of Medicine in Houston, Texas in 
2007 and sits on the MRC Council, says 
that these changes are making a big dif-
ference at Imperial. Since October 2007, 
for example, Imperial, like most major US 
medical schools (with the exceptions of 
Baylor and Harvard), has been running 
its own hospitals through the Imperial 
College Healthcare NHS Trust. Sch-
neider says that the new arrangement 
has made it easier for biologists and 
other laboratory scientists at Imperial 
to address medical questions, working 
with clinicians at world-famous London 
hospitals in the Trust, such as Charing 
Cross, Hammersmith, and St. Mary’s. 
“Our scientists are very motivated to 
have their work applied to biomedical 
problems,” he says, “but this involves 
a dialogue that doesn’t always happen 
spontaneously.” Schneider adds that 
despite the US advantage of scale, the 
UK can excel through the quality of its 
institutions and the advantages of work-
ing with the NHS.
Ninety percent of the Cooksey objec-
tives have been met, Borysiewicz con-
tends, with most of the outstanding 
issues related to informatics—the quest 
to integrate National Health Service 
patient records into a single research 
database. He notes that while the NHS 
has developed a single health records 
system in Scotland, the much larger 
English system remains fragmented.
Borysiewicz’s tenure has also been 
marked by efforts to broaden MRC’s inter-
national remit, both in terms of more col-
laborations with partners overseas and in 304 Cell 140, February 5, 2010 ©2010 Elsevaddressing global health issues, such as 
infectious diseases. He’s especially proud, 
for example, of a new joint initiative involv-
ing France and Germany (and other Euro-
pean Union member states) on research 
into Alzheimer’s disease, dementia, and 
other neurodegenerative conditions (http://
europa.eu/rapid/ pressReleasesAction.
do? reference=IP/09/1171&format=HT). 
“An analysis between the three coun-
tries showed that there was immense 
complementarity between skills in this 
field in Britain, France and Germany,” he 
says. “That is now being used as a pilot to 
see if this approach to funding will work. 
At the moment, its 30 million euros and 
we’re looking to it to be far larger in due 
course.”
Additionally, the MRC has been 
engaged in an ambitious program to 
rebuild its largest intramural laborato-
ries. Work started in summer 2008 on 
the construction of a new, £200 million 
facility in Cambridge that will house 
the 400 researchers at perhaps MRC’s 
most famous institute, the Laboratory 
of Molecular Biology. And the agency is 
working with the Wellcome Trust, Can-
cer Research UK, and University College 
London to build a UK Centre for Medical 
Research and Innovation (UKCMRI) in 
central London, which would house up 
to 1500 staff with the goal of becoming 
Europe’s premier biomedical research 
facility.
UKCMRI was announced by Gordon 
Brown in December 2007 and is due to 
open in 2014, but construction work has 
yet to begin, and with Britain’s public 
finances in crisis, doubts persist that the 
£500 million project will see the light of 
day. Borysiewicz says he is “very con-
fident” that the mammoth project will 
proceed even if, as is widely expected, 
a Conservative government gets elected 
this year. “I believe, from the conversa-
tions I’ve had, that they are very sup-
portive of the project,” he says. “But we’ll 
have to wait and see.”
Another critical issue for the MRC is its 
position relative to the Wellcome Trust, 
the UK charity whose £590 million annual 
budget almost matches the MRC’s £720 
million. (In the United States, by contrast, 
the largest philanthropic organization, 
the Howard Hughes Medical Institute, 
spent $700 million last year on research, 
less than one-fortieth of the NIH budget.) ier Inc.Pressed by researchers at the Edin-
burgh meeting in December last year, 
Borysiewicz conceded that Wellcome’s 
November 2009 announcement that it 
will concentrate its support on 7 year 
“investigator awards” to a smaller num-
ber of exceptional researchers could 
intensify demands on MRC’s own grants 
(ht tp://www.wellcome.ac.uk /News/
Media-of f ice/Press-releases/2009/
WTX057403.htm). “You’re going to see 
a greater push from young investiga-
tors, who need our grants before they 
can apply for £1 million from Wellcome,” 
Borysiewicz said. “So I see us being put 
under more pressure, at a time when we 
won’t have much financial leeway.” Well-
come Trust’s Walport denies that this will 
occur. “We support very good people 
and we’ll continue to do that,” he says. 
“I’m not convinced that [the change] will 
put more pressure on the MRC.”
Another important issue for the MRC 
is the future of its London headquarters, 
and the associated issue of autonomy. 
At the end of this year, the lease expires 
on its imposing Georgian abode in cen-
tral London. This coincides with pow-
erful pressure from the government to 
relocate with the other six UK research 
councils to a dismal campus in Swin-
don, 80 miles west of London. At the 
end of last year, Borysiewicz agreed to 
a compromise with the Department for 
Business, Innovation and Skills (BIS) that 
will, he says, keep 90–100 senior staff at 
a new location in London, with another 
120 moving to Swindon. Observers say 
that the split is the best outcome that the 
MRC could have hoped for but will none-
theless damage staff morale. “It’s going 
to weaken the MRC a lot,” says one offi-
cial, who knows the research council 
well. The move also carries overtones of 
the recurrent threat that the MRC, which 
is due to celebrate its centenary in 2013, 
might conceivably be merged with the 
other research councils in a bid to ratio-
nalize operations. “I think it is unlikely 
to happen,” says Borysiewicz. “But you 
can’t discount it altogether.”
All of this takes place against a back-
drop of sharply deteriorating public 
finances in Britain. The general view is 
that research funding—after doubling 
over the last 10 years—will now face 
cuts of 10% or more over the next 2 
or 3 years, probably under an emer-
gency budget that is expected to be 
announced by the winner of the general 
election, which is likely to be in May. 
What happens when these cuts emerge 
remains “open to question,” says Bell, 
whose OSCHR office is already coor-
dinating a March budget submission 
for this year’s Comprehensive Spend-
ing Review, which sets UK government 
spending plans every 3 years. Bell thinks 
he might be asked to repeat the exercise 
after the election. “It may be that some 
sections of science will be largely pro-tected” from the anticipated cuts, Bell 
says, and even if they aren’t, “we can 
continue to be pretty successful, pro-
vided that any contraction is organized 
in ways that won’t damage the entire 
medical research enterprise.”
In a relatively short time at the MRC, 
most observers agree, Borysiewicz has 
succeeded in starting to build the stron-
ger partnerships demanded by the Cook-
sey Report, to nurture the translation 
of research results into healthcare. As 
Walport puts it: “He’s demonstrated that Cell 140they can support both basic science and 
clinical research.” “Borys will be missed 
for his impeccable scientific taste and 
for his immense personal and political 
skills,” says Schneider. “He’s also had the 
good fortune to come into the MRC at a 
very dynamic time. I’d be worried about 
replacing him in any circumstances, and 
it’ll be even more of a challenge now, given 
the funding outlook. That being said, the 
MRC has been around for almost 100 
years, and I’m sure it can attract a top-
rate individual to lead it.”
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